drugset / Trial / NCT06258304
A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Timeline
- Start
- 2024-05-08
- Primary completion
- 2026-04
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GIGA-564 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | GIGA-564 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | GIGA-564 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | GIGA-564 | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | GIGA-564 | Monoclonal antibody | 20 mg/kg | Intravenous |
Indications
No indication recorded.